원발성 면역결핍증 치료제 시장 규모, 점유율, 성장 분석 : 적응증별, 약물 종류별, 투여 경로별, 연령층별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Primary Immunodeficiency Therapeutics Market Size, Share, and Growth Analysis, By Indication, By Drug Class, By Route of Administration, By Age Group, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1738062
리서치사:SkyQuest
발행일:2025년 05월
페이지 정보:영문 186 Pages
라이선스 & 가격 (부가세 별도)
한글목차
원발성 면역결핍증 치료제 세계 시장 규모는 2023년에 28억 달러로 평가되었으며, 2024년 29억 6,000만 달러에서 2032년에는 46억 1,000만 달러로 성장하고, 예측 기간(2025-2032년) 동안 CAGR 5.7%로 성장할 전망입니다.
세계 원발성 면역결핍증(PI) 치료제 시장은 인지도 향상, 진단법 개선, 맞춤형 치료 접근성 강화 등을 배경으로 완만한 성장세를 보이고 있습니다. 면역반응에 영향을 미치는 유전적 결함으로 인한 원발성 면역결핍증으로 분류되는 장기 희귀질환은 약 450여 종에 달하며, 면역글로불린 보충, 표적 생물학적 제제, 줄기세포 이식 등 장기적인 치료에 대한 니즈가 증가하고 있습니다. 유전자 기술 및 스크리닝 방법의 발전으로 조기 진단이 용이해지면서 이러한 수요는 더욱 증가하고 있습니다. 북미와 유럽의 규제기관은 희귀질환 치료제 개발에 우선순위를 두고 있으며, 이에 따라 신약에 대한 투자가 증가하고 있습니다. 또한, PI 질환이 국가 희귀질환 이니셔티브로 지정됨에 따라 자금이 지원되고 치료 장벽이 완화되고 있으며, 환자 옹호 활동과 민관 파트너십은 특히 개발도상국에서 접근성을 개선하는 데 필수적입니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
원발성 면역결핍증 치료제 시장 규모 : 적응증별 & CAGR(2025-2032년)
시장 개요
흔한 변이성 면역결핍증(CVID)
X-연관 아감마글로불린혈증(XLA)
중증 복합 면역결핍 장애(SCID)
위스코트-알드리치 증후군(WAS)
하이퍼-IgM 증후군(HIGM)
원발성 면역결핍증 치료제 시장 규모 : 약물 종류별 & CAGR(2025-2032년)
시장 개요
면역글로불린 보충 요법
면역조절제
줄기세포 치료
유전자 치료
항생제
원발성 면역결핍증 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)
시장 개요
정맥내(IV)
피하(SC)
근육내(IM)
원발성 면역결핍증 치료제 시장 규모 : 연령층별 & CAGR(2025-2032년)
시장 개요
소아
성인
원발성 면역결핍증 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)
시장 개요
병원
전문 약국
온라인 약국
원발성 면역결핍증 치료제 시장 규모 & CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
최근의 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년비 비교(2022-2024년)
주요 기업 개요
CSL Behring(USA)
Grifols(Spain)
Octapharma(Switzerland)
Takeda Pharmaceutical Company Limited(Japan)
Biotest AG(Germany)
ADMA Biologics(USA)
Bio Products Laboratory(BPL)(USA)
LFB SA(France)
Kedrion Biopharma S.p.A.(Italy)
Pfizer Inc.(USA)
Orchard Therapeutics(UK)
Rocket Pharmaceuticals(USA)
Bluebird Bio(USA)
China Biologic Products Holdings(China)
GC Pharma(South Korea)
Baxter International Inc.(USA)
X4 Pharmaceuticals(USA)
Novartis AG(Switzerland)
Sanofi S.A.(France)
Bristol Myers Squibb(USA)
결론과 제안
ksm
영문 목차
영문목차
Global Primary Immunodeficiency Therapeutics Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 2.96 billion in 2024 to USD 4.61 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).
The global primary immunodeficiency (PI) therapeutics market is witnessing a gradual expansion, driven by increased awareness, improved diagnostics, and enhanced access to tailored treatments. With around 450 rare long-term disorders classified as primary immunodeficiencies resulting from genetic defects affecting immune responses, there is a rising need for long-term therapies like immunoglobulin replacement, targeted biologics, and stem cell transplants. Advances in genetic technologies and screening methods have facilitated earlier diagnoses, further fueling this demand. Regulatory bodies in North America and Europe are prioritizing orphan drug development, resulting in heightened investment in new medications. Additionally, the designation of PI diseases as national rare disease initiatives is attracting funding and reducing treatment barriers, while patient advocacy and public-private partnerships are essential in improving access, especially in developing regions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Primary Immunodeficiency Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Primary Immunodeficiency Therapeutics Market Segments Analysis
Global Primary Immunodeficiency Therapeutics Market is segmented by Indication, Drug Class, Route of Administration, Age Group, Distribution Channel and region. Based on Indication, the market is segmented into Common Variable Immunodeficiency (CVID), X-linked Agammaglobulinemia (XLA), Severe Combined Immunodeficiency Disorders (SCID), Wiskott-Aldrich Syndrome (WAS) and Hyper-IgM Syndrome (HIGM). Based on Drug Class, the market is segmented into Immunoglobulin Replacement Therapy, Immune-modulating Agents, Stem Cell Therapy, Gene Therapy and Antibiotics. Based on Route of Administration, the market is segmented into Intravenous (IV), Subcutaneous (SC) and Intramuscular (IM). Based on Age Group, the market is segmented into Pediatric and Adult. Based on Distribution Channel, the market is segmented into Hospitals, Specialty Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Primary Immunodeficiency Therapeutics Market
Recent advancements in diagnostic technologies, particularly next-generation sequencing (NGS) and genetic screening, have substantially reduced the time needed to diagnose primary immunodeficiency (PI) diseases. Early diagnosis enables prompt initiation of treatment, leading to improved therapeutic outcomes by minimizing infection burdens. This heightened diagnostic accuracy enhances the management of PI, fosters greater patient compliance, and ultimately boosts quality of life. As a result, there is a growing demand for PI therapeutics in the market. The positive correlation between early diagnosis and effective treatment underscores the critical role of advanced diagnostics in driving growth within the global primary immunodeficiency therapeutics market.
Restraints in the Global Primary Immunodeficiency Therapeutics Market
A significant challenge facing the global primary immunodeficiency therapeutics market is the high cost associated with immunoglobulin therapies, gene treatments, and stem cell therapies. This financial burden is particularly acute in low-income countries, where patients struggle to afford crucial, potentially life-saving treatments. Additionally, rising expenses related to plasma collection have further inflated the costs of immunoglobulin therapies, a trend observed even in developed nations. These financial obstacles contribute to increasing reimbursement difficulties, ultimately restricting patient access to these therapies and making it challenging for healthcare systems to establish and sustain long-term treatment regimens effectively.
Market Trends of the Global Primary Immunodeficiency Therapeutics Market
The Global Primary Immunodeficiency (PI) Therapeutics market is witnessing a transformative trend driven by the integration of artificial intelligence (AI) into individualized immunoglobulin dosing. This cutting-edge approach tailors treatment based on specific patient parameters, such as weight, infection frequency, and metabolic rate, thereby optimizing therapeutic regimens and mitigating side effects. By enhancing treatment adherence and maximizing resource efficiency, AI is poised to redefine patient care in the PI sector. Ongoing clinical trials aim to validate these innovative dosing algorithms across diverse populations, signaling a pivotal shift towards more personalized medicine that could significantly improve patient outcomes, driving market growth in this segment.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Primary Immunodeficiency Therapeutics Market Size by Indication & CAGR (2025-2032)
Market Overview
Common Variable Immunodeficiency (CVID)
X-linked Agammaglobulinemia (XLA)
Severe Combined Immunodeficiency Disorders (SCID)
Wiskott-Aldrich Syndrome (WAS)
Hyper-IgM Syndrome (HIGM)
Global Primary Immunodeficiency Therapeutics Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Immunoglobulin Replacement Therapy
Immune-modulating Agents
Stem Cell Therapy
Gene Therapy
Antibiotics
Global Primary Immunodeficiency Therapeutics Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Intravenous (IV)
Subcutaneous (SC)
Intramuscular (IM)
Global Primary Immunodeficiency Therapeutics Market Size by Age Group & CAGR (2025-2032)
Market Overview
Pediatric
Adult
Global Primary Immunodeficiency Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospitals
Specialty Pharmacies
Online Pharmacies
Global Primary Immunodeficiency Therapeutics Market Size & CAGR (2025-2032)
North America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
US
Canada
Europe (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
